SP-A对感染MO的盘羊杂交羊治疗效果及机制探索

绵羊支原体肺炎对养羊业危害严重，临床上缺乏治疗该病的特效药，研制该病特效药，必须完成临床药物疗效实验，其中建立该病的疾病模型是迫切需要解决的问题。肺表面活性物质相关蛋白A（SP-A）是一种亲水性糖蛋白，在促进宿主肺部先天性防御肺炎支原体感染过程中发挥了重要作用。本研究以绵羊SP-A为研究对象，以易感绵羊肺炎支原体（MO）的盘羊和巴什拜羊的杂交后代作为模型动物，通过筛选MO强毒株和回传易感羊获得含有MO强毒株的肺组织作为攻毒材料，接种盘羊杂交羊，建立MO人工感染模型，并通过行为学临床评分，肺脏病变评分，检测各项指标建立模型评价体系。在此基础上，研究SP-A对感染MO的盘羊杂交羊治疗效果，最佳治疗剂量、治疗时间，并探究SP-A在改善临床表现的同时，是否会改善肺部炎症、细胞因子过度表达引起的肺损伤、各脏器MO载荷量、免疫抑制，以期为SP-A在绵羊支原体肺炎的临床应用、治病机制研究提供基础与支持。

Mycoplasma pneumonia in sheep, a major infectious diseases without specific drug in clinic， seriously harm the healthy development of sheep industry. For developing a specific drug used for treating this disease, clinical experiments on the evaluation of its therapeutic effect must be completed necessarily. In which, establishing animal disease models successfully is an important problem in urgent need of solution. Pulmonary surfatcant-associated protein A (SP-A), a kind of hydrophilic glycoprotein, plays an important role in promoting the innate defense of host’s lung against Mycoplasma ovipneumoniae (MO). SP-A is the research object of this study, argali hybrid lambs produced from parents of male Argali sheep and female Bashbay sheep are used to establish models. In this study, in order to the establish artificial infection model of MO successfully, the virulent strain of MO sifted out is used to infect susceptible sheep, its lungs containing the virulent strain of MO are collected and used to infect subsequently. After that, the model evaluation system is established by behavioral clinical score, lung disease score and various indicators of detection. Aiming to provide the basis and support for the clinical application of SP-A in treating Mycoplasma pneumonia in sheep and its cure mechanism, the therapeutic effect of SP-A on argali hybrid lambs infected with MO, the best therapeutic dose and time are studied on this basis. In addition, the questions whether lung inflammation and lung injury caused by over expression of cytokines will be relieved, whether the load of MO will reduce and whether immunodepression will be decreased while improving clinical performance are explored.